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The objective was to identify proteins differentially expressed in vaginal cancer to elucidate relevant cancer-related proteins. A total
of 16 fresh-frozen tissue biopsies, consisting of 5 biopsies from normal vaginal epithelium, 6 from primary vaginal carcinomas and 5
from primary cervical carcinomas, were analysed using two-dimensional gel electrophoresis (2-DE) and MALDI-TOF mass
spectrometry. Of the 43 proteins identified with significant alterations in protein expression between non-tumourous and tumourous
tissue, 26 were upregulated and 17 were downregulated. Some were similarly altered in vaginal and cervical carcinoma, including
cytoskeletal proteins, tumour suppressor proteins, oncoproteins implicated in apoptosis and proteins in the ubiquitin–proteasome
pathway. Three proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and
five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-
hydrolase beta). The identified proteins imply involvement of multiple different cellular pathways in the carcinogenesis of vaginal
carcinoma. Similar protein alterations were found between vaginal and cervical carcinoma suggesting common tumourigenesis.
However, the expression level of some of these proteins markedly differs among the three tissue specimens indicating that they might
be useful molecular markers.
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Primary carcinoma of the vagina (PCV) accounts for approxi-
mately 1–2% of all gynaecological malignancies and predomi-
nantly affects postmenopausal women (Pettersson, 1999; Beller
et al, 2006). However, the majority (85–90%) of malignancies
arising in the vagina are metastatic lesions. Histologically most
PCV cases are squamous cell carcinomas (Pettersson, 1999; Beller
et al, 2006). As PCV is rare, little is known about aetiological and
prognostic factors or about biological markers. The only
established prognostic factor is tumour stage. It has been
suggested that vaginal and cervical carcinomas share a common
aetiology, because vaginal tumours tend to occur as a second
primary malignancy in patients with a history of cervical dysplasia
and/or neoplasia even after hysterectomy for these disorders
(Choo and Anderson, 1982; Eddy et al, 1991; Kirkbride et al, 1995).
Cervical squamous carcinomas are strongly associated with human
papillomavirus (HPV) infection, with a prevalence of almost 100%
(Bosch and Munoz, 2002). However, HPV-DNA has been identified
in PCV in only about 50% of the cases (Daling and Sherman, 1992;
Hildesheim et al, 1997). Cervical carcinomas occur in younger
women, usually under the age of 60, whereas PCV is mainly found
in older women. It has been proposed that PCV may develop in
different ways, either through HPV-induced mutation or through
other non-HPV factors that are also likely to play a role in the
aetiology of PCV.
It is sometimes difficult to discriminate between PCV, cervical
carcinoma and metastatic lesions, especially in patients with
recurrent disease. Correct diagnosis is important for choice of
therapy, prognosis and follow-up. Treatment and estimated
tumour aggressiveness are still based on crude histopathological
and clinical parameters, in both PCV and cervical carcinoma,
resulting in individual cases of under- and over-treatment.
Increased biological knowledge of PCV and cervical carcinoma
is needed to understand the molecular mechanisms of carcino-
genesis and to find tumour-specific markers for diagnosis,
prognosis and treatment.
Proteomic analysis provides an effective tool for understanding
tumour biology and for establishing tumour-specific markers or
protein profiles for certain clinical indications. Several genomic
and proteomic studies have been carried out during the past
decade to analyse gene expression and protein profiles for a variety
of malignancies to find diagnostic, prognostic and predictive
markers. 2-DE in combination with mass spectrometry has most
commonly been used. Some tumour-specific markers for clinical
use have been identified by proteomic studies, for example TAO1
and TAO2, are two effective markers for distinguishing primary
lung adenocarcinoma from metastasised adenocarcinoma origi-
nating in other organs (Franzen et al, 1997; Hirano et al, 1997).
These proteins were both later identified as napsin A (Chuman
et al, 1999). Furthermore, cytokeratins and vimentin are used in
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sthe diagnosis of lung cancer and lower intestinal cancer (Cathro
and Stoler, 2002; Liu et al, 2004).
Only a few proteomic studies have been conducted in cervical
carcinoma (Bae et al, 2005; Choi et al, 2005; Lee et al, 2005; Lin
et al, 2006), for which proteins such as annexin A2, tropomyosin 1
and 2, peroxiredoxin 2 and HSP 27 have been pointed out as
potential diagnostic markers.
To date, only two studies have been carried out to investigate
gene and protein expressions in vaginal carcinoma. The first study
analysed the pattern of genomic imbalances in vaginal squamous
cell carcinomas using comparative genomic hybridisation, which
revealed that 70% of vaginal carcinomas carry relative copy
number increases that map to chromosome arm 3q (Habermann
et al, 2004). This pattern of genomic imbalances in PCV was
strikingly similar to the one observed in cervical carcinomas
(Heselmeyer et al, 1996) further strengthening the hypothesis of
related aetiological pathways. Another study examined protein
expression profiles using 2-DE in primary vaginal carcinoma
compared with cervical carcinoma. Correlation analysis revealed
high correlation between the tissue specimens. However,
hierarchical cluster analysis correctly classified the samples in
two groups (Hellman et al, 2004).
The purpose of this study was to identify the proteins that were
differentially expressed in normal tissue and in vaginal and
cervical cancer tissue by using the 2-DE protein separation
technique and MALDI-TOF mass spectrometry to elucidate
carcinogenetic pathways, to find out if they are functionally
related and identify tumour-specific markers.
MATERIALS AND METHODS
Patient tissue samples, 2-DE gel electrophoresis and image
analysis
Sixteen tissue biopsies, approximately 3 3mm, were obtained
and snap frozen. The samples consisted of five normal vaginal
epithelium biopsies, as well as six primary vaginal carcinoma
and five primary cervical carcinoma biopsies. This set of samples
was previously described in a publication from our laboratory
(Hellman et al, 2004). The histopathological characteristics of the
samples are presented in Table 1.
The normal vaginal tissue samples were included as a baseline
for the normal vaginal epithelium proteome and to ensure an
effective comparison with vaginal cancer.
The rationale for including the cervical cancer samples was to
elucidate similarities and differences between cervical and vaginal
cancers at the proteome level.
All tumour biopsies were obtained from patients with histo-
pathologically confirmed diagnosis of either vaginal or cervical
cancers. To guarantee sample representativity, both cytological
and histological evaluations were carried out on all samples, and
only in those where both examined features corresponded were
included in the study as previously described (Hellman et al,
2004). Informed consent was obtained before all sampling and the
Stockholm County Council ethics committee gave its approval
(Dnr: 97–244).
Sample preparation All tissue samples were prepared according
to the previously described method (Hellman et al, 2004). The
proteins were extracted and solubilised in lysis buffer containing
9 M urea (BioRad, Hercules, CA, USA) 2 M thiourea (USB,
Cleveland, OH, USA), 5% Resolyte (BDH, Poole, UK), 65mM
dithiothreitol (BioRad), 1 M EDTA (Merck, NJ, USA), 0.5% v/v
NP-40 (Nonidet P-40; USB), 25mM CHAPS, 0.1% PMSF (phenyl-
methylsulphonyl fluoride) and 1% benzamidine (Sigma, Missouri,
USA). Protein concentration was determined by the Bradford
protein analysis method (Bradford, 1976).
Electrophoresis
First dimension Iso-electric Focusing (IEF): The proteins are
separated according to their iso-electric point in an immobilised
pH gradient gel (IPG strip), see below.
Second dimension Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS–PAGE): The proteins that are focused in the
immobilised pH gradient are further separated according to their
molecular weight in a large size 10–13% gradient SDS–PAGE gel,
25 20cm 1.5mm.
Before application, the first dimension samples were diluted to
0.25mgml
 1 in rehydration buffer containing urea, thiourea,
CHAPS, Triton X-100 (GE Healthcare, Amersham, UK) IPG buffer
4–7 (BioRad) and a few grains of bromphenol blue (Merck, );
300ml were applied to 17-cm long IPG strips pH 4–7 (BioRad). IEF
was performed in an IEF Cell (BioRad) for 22.5h including
rehydration until approximately 52900Vh were reached.
The IPG strips were subsequently treated in two steps before
loading the 2-DE gradient gels. The first step was to reduce the
proteins using dithiothreithol and the second was equilibration to
alkylate the free SH-groups using iodoacetamide (Sigma).
The second dimension, SDS–PAGE, was performed in gradient
gels with piperazinediacrylamide (PDA; BioRad) as a cross-linker,
in an ISO DALT tank (GE Healthcare) with the capacity to run
10 gels simultaneously. The electrophoresis was carried out at
constant power, 100V using an EPS2A200 power supply (Hoefer)
at 121C for approximately 19h. After electrophoresis all gels were
then incubated in fix solution, containing 30% ethanol (Kemetyl,
Haninge, Sweden) and 10% acetic acid (Sigma), and subsequently
stained with silver nitrate (Merck) (Rabilloud et al, 1994).
Following development, a GS-710 (BioRad) flat bed densitometer
was used to scan all high-resolution gels at a resolution of
105.8mm. The gels were matched to each other using PDQuest
software, version 7.3.0 (BioRad). Background was subtracted and
individual polypeptides quantified as p.p.m. of the total integrated
optical density. Each spot was given a unique id number. All
differentially expressed spots were individually examined to ensure
that they were representative and were of high quality.
Excision Proteins that were statistically significantly up- or
downregulated by using Mann–Whitney statistical analysis and
t-test (Po0.05), were selected for identification by mass spectro-
metry. Proteins were localised, excised manually, and transferred
Table 1 Clinical and histopathological data
No Sample Type of sample Age Stage Histology Grade
1 V24N Normal vaginal tissue 48
2 V25N Normal vaginal tissue 70
3 V26N Normal vaginal tissue 56
4 V37N Normal vaginal tissue 78
5 V38N Normal vaginal tissue 78
6 V29T Vaginal carcinoma 83 I SCC
7 V30T Vaginal carcinoma 54 I AC
8 V31T Vaginal carcinoma 89 I SCC
9 V32T Vaginal carcinoma 62 I SCC Low
10 V33T Vaginal carcinoma 78 I SCC Medium
11 V34T Vaginal carcinoma 75 IIB SCC High
12 Cx40 Cervical carcinoma 45 IIB SCC Low
13 Cx41 Cervical carcinoma 41 1B2 AC
14 Cx42 Cervical carcinoma 63 IIA SCC Low
15 Cx43 Cervical carcinoma 59 IB2 SCC Medium
16 Cx44 Cervical carcinoma 65 IB1 SCC Medium
SCC¼squamous cell carcinoma; AC¼adenocarcinoma.
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sto sterile tubes. Some low abundant spots were pooled from
different gels to increase the signal in mass spectrometric analysis.
All excisions were performed in an LAF bench to minimise risk of
contamination. Protective clothing, hair protection and extra arm
protection were used. By maintaining these high standards
keratins and other contaminants were kept low.
Mass spectrometry
In-gel digestion for peptide mass fingerprint analysis was per-
formed manually using trypsin (Hellman, 2002), and the digests
were concentrated and desalted using mZipTip C18 (Millipore,
Billerica, MA, USA) as recommended by the manufacturer.
Peptides were eluted onto the MALDI target plate in 70%
acetonitrile/0.1% trifluoroacetic acid containing half saturated a-
cyano-4-hydroxycinnamic acid as matrix. Peptide mass finger-
printing was performed using MALDI-TOF MS on an Ultraflex
TOF/TOF III (Bruker Daltonics, Bremen, Germany).
Trypsin autolytic fragments of charged masses 842.50, 2211.10
and 3337.76Da were used as internal standards for spectra calibra-
tion. Data generated were screened in a protein sequence database
(NCBInr, current version) using a mass tolerance p20p.p.m.
Search engines used were Mascot (http://www.matrixscience.com)
or ProFound (http://prowl.rockefeller.edu/prowl-cgi/). One missed
cut was allowed and no restriction was made regarding species,
size or pI; that is, the search was unbiased.
The above protocol for MALDI-TOF analysis has a sensitivity of
low femtomole amounts of standard 2-DE gel-separated proteins.
For a positive identification using peptide mass fingerprinting,
protein scores greater than 72 were considered significant
(Po0.05), as calculated by the MASCOT scoring algorithm.
In addition, at least five matching peptides had to be found and
more than 15% of the target protein’s sequence had to be covered.
We also considered and compared the practical and theoretical
pI and Mw values of matching proteins.
Data processing/data analysis
Both quantitative and qualitative 2-DE datasets were generated
from PDQuest, a 2-DE software analysis program as previously
described (Hellman et al, 2004).
The differentially expressed protein spots were selected for
identification.
RESULTS
Fresh-frozen tissue biopsies were subjected to 2-DE and analysed
for both qualitative and quantitative differences in the expression
of multiple proteins. An average total of 1373 spots were resolved
on 25 20cm 2-DE gels, and between 75 and 82% of the spots
were matched among all gels. Silver stain was used to visualise gel
spots (Figure 1).
Using PDQuest, the protein expression pattern in the different
tissue specimens (normal vaginal tissue, vaginal cancer and
cervical cancer) was analysed.
Mann–Whitney statistical analysis (Po0.05) revealed 67
proteins that were differentially expressed in normal vaginal
tissue, vaginal cancer and cervical cancer. A similar analysis was
carried out on these three groups of samples using Student’s t-test,
and 94 protein spots differed significantly. The differential analysis
takes into consideration both the qualitative and quantitative
changes observed between these sets of samples. Furthermore,
these two separate datasets correctly classified the three groups of
samples using hierarchical cluster analysis.
We excised a total of 104 spots with statistically significant
variability in the expression pattern (Po0.05) between normal
vaginal tissue, cervical cancer and vaginal cancer for identification
by MALDI-TOF mass spectrometry. One obvious limitation when
working with clinical samples is getting sufficient material for
detailed analysis. Therefore, a relatively large number of the
protein spots in the datasets for cluster analyses could not be
identified. However, 61 proteins were clearly identified and among
these, 43 proteins had prominent protein expression alterations
(approximately 2- to 3-fold increase/decrease) as compared with
normal tissue; 26 proteins were upregulated (Table 2) and 17
downregulated (Table 3). The differential expressions of some of
these proteins are shown in Figure 2.
Of the 26 upregulated proteins, 3 were upregulated in vaginal
carcinoma only, compared with normal vaginal tissue and cervical
cancer (DEAD box protein (DDX48 or EIF4A3), erbB3-binding
protein (Ebp1) and biliverdin reductase). In cervical carcinoma,
three proteins were clearly upregulated compared with vaginal
carcinoma and normal vaginal tissue (thiol-specific antioxidant
prot, annexin A2 and alfa-2-actin). In both cancer specimens, 20
proteins were upregulated compared with normal vaginal tissue
(tyr-3-monooxygenase, nuclear chloride channel prot, apolipopro-
tein (2), proteasome activator hP A28 beta, RAB 1B (RAS oncogen
47
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7 4
10
150
Mr
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150
10
Cervical carcinoma Vaginal carcinoma
Figure 1 2-DE gel images of primary vaginal and cervical carcinoma.
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sfamily), serpin B6 (thrombin inhib) (2), GST M2-2 as well as M1
(2), HSP 27, aldehyde dehydrogenase, (eukaryotic translation)
elongation factor, GDP dissociation inhibitor 2, capping prot (actin
filament), DJ-1, PIMT, chaperonin TCP1, 14-3-3 protein theta and
NM23). Of the 17 downregulated proteins, 6 different proteins
showed low expression in both vaginal and cervical carcinoma
Table 2 Upregulated proteins (26) in vaginal and cervical carcinoma compared to normal vaginal tissue
Arbitrary (relative)
intensity
a Empiric In silica
Sample
ID Result Normal
Vaginal
cancer
Cervical
cancer pI MW pI MW
Accession
number
% Sequence
coverage
Number of
matched peptides
1107 14-3-3 protein theta 2 4 3 4.5 30 4.7 28 NP_006817 45 17
1123 Tyr-3-monooxygenase (14-3-3 zeta) 2 4 3 4.8 30 4.8 28 NP_036611 47 11
3122 Nuclear chloride channel prot 2 4 4 5.3 32 5.0 27 AAD26137 43 7
4004 Thiol-specific antioxidant prot
(peroxiredoxin 2)
1 1 4 5.6 20 5.9 18 CAA57764 24 5
4103 Proapolipoprotein 2 4 4 5.5 25 5.4 29 AAA51747 76 29
4124 Proteasome activator hP A28 beta 2 4 4 5.4 28 AAF02218 37 10
4134 RAB 1B (RAS oncogen family) 1 4 4 4.6 22 5.6 22 NP_112243 46 8
4306 Serpin B6 (thrombin inhib) 2 3 3 5.6 60 5.2 43 NP_109591 27 9
5107 Alfa-2-actin 2 2 4 5.9 30 5.2 42 NP_001604 41 13
5114 Apolipoprotein A1 2 3 3 5.8 30 5.6 31 NP_000030 27 7
5121 GST (GSTP1_HUMAN) 2 4 4 5.9 20 5.5 23 CAA30894 61 13
5129 Capping prot (actin filament) (CAPZB) 2 4 4 6 30 6.5 30 CAH71390 31 9
6016 NM23 (nucleoside difosfatkinase) 2 4 3 6.2 15 5.8 20 NP_937818 32 5
6114 HSP 27 2 4 4 6.1 30 6.0 23 NP_001531 41 9
6414 Aldehyd dehydrogenase (ALDH9A1) 2 4 3 6.1 80 5.4 52 AAB06721 15 8
7017 DJ-1 2 4 4 6.6 20 6.3 20 NP_009193 56 11
7126 PIMT 2 4 3 6.4 20 6 25 AAA90934 44 7
7312 Serine peptidase inhibitor (Serpin B6) 2 3 2 6.2 65 5.9 43 NP_109591 42 14
8114 GST M2-2 samt M1 2 4 3 6.0 26 Gi4557966 71 16
8211 Biliverdin reductase A 2 4 2 6.6 55 6.1 34 AAH05902 20 6
8227 Annexin A2 1 1 4 6.9 50 7.7 39 AAH09564 18 6
8324 Eukar. Transl Elongation factor 2 4 4 6.7 80 6.3 50 NP_001395 33 13
8330 DEAD box (eukaryotic translation initiation
factor 4A, isoform 3 (EIF4A3), eller DDX48
mRNA).
2 4 2 6.7 80 6.3 47 NP_055555 23 12
8404 GDP dissociation inhibitor 2 2 4 4 6.7 80 5.9 46 CAI13363 49 16
8422 Erb B2 binding protein (erbB3 binding
protein EBP1)
2 4 2 6.7 80 7.2 38 AAD00646 18 12
8511 Chaperonin (containing TCP1, subunit 3
(gamma))
2 3 3 6.6 85 6.1 61 AAH08019 34 18
1, extremely low; 2, low; 3, moderately; 4, high;
aArbitrary (relative) intensity.
Table 3 Downregulated (17) proteins in vaginal and cervical carcinoma compared to normal vaginal tissue
Arbitrary (relative)
intensity
a Empiric In silica
Sample
ID Result Normal
Vaginal
cancer
Cervical
cancer pI MW pI MW
Accession
number
%sequence
coverage
Number of
matched peptides
515 Calreticulin 4 2 2 4.4 95 4.3 48 NP_004334 63 20
1105 14-3-3 protein epsilon 4 4 3 4.6 30 4.6 29 NP_006752 57 16
1242 Tropomyosin 2 (beta) 4 1 1 4.7 45 4.6 33 NP_998839 58 24
1246 Sarcomeric tropomyosin kappa 4 4 1 4.6 60 4.7 33 AAT68294 50 22
1313 Vimentin 4 1 1 4.8 65 5.1 54 CAA79613 36 20
1324 Vimentin (+keratin) 4 1 1 5 60 5.1 53 CAA79613 53 31
1404 Rnas inhib chain A 4 4 1 4.6 80 4.7 52 NP_002930 65 21
1422 Prolyl-4-hydrolase beta 4 4 1 4.9 80 4.8 58 NP_000909 45 22
6439 hnRNP H1 3 4 2 6.2 80 5.8 49 CAG33059 37 12
6615 Gelsolin b och a 4 2 2 6 100 5.6 83 NP_937895 36 24
7702 Vinculin 4 2 2 (3) 6.7 60 5.6 88 CAI39669 14 9
7703 Filamin 4 2 1 6.2 45 5.9 89 AAH14654 22 12
7711 Filamin A 4 1 1 6.2 4100 5.7 105 AAH67111 34 23
7716 Filamin A 3 1 1 6.3 4100 5.7 280 BAD52436 14 24
7720 Filamin A 3 1 1 6.3 4100
7722 Vinculin 4 2 3 6.4 100 5.8 117 NP_003364 38 34
9511 WD repeat 3 3 2 6.9 95 6.2 67 NP_059830 58 33
1, extremely low; 2, low; 3, moderately; 4, high;
aArbitrary (relative) intensity.
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scompared with normal vaginal tissue (calreticulin, tropomyosin 2
beta, vimentin, gelsolin, vinculin and filamin). Three proteins were
distinctly downregulated in cervical carcinoma compared with
vaginal cancer (sarcomeric tropomyosin kappa, Rnas inhib chain
A and prolyl-4-hydrolase beta). For the distribution of proteins
that were uniquely and similarly expressed in vaginal and cervical
carcinoma see Figure 3. Furthermore, cluster analysis was
performed using the expression patterns of some proteins that
were downregulated (Figure 4) and uniquely expressed (Figure 5)
in both vaginal and cervical carcinoma.
DISCUSSION
This study is the first proteomic study to analyse and identify
proteins expressed in primary vaginal carcinoma and normal
vaginal tissue by using MS. The expression profiles have also been
compared with primary cervical carcinoma.
In all, we identified 43 proteins with significantly altered
expression levels that discriminated well between non-tumourous
and cancer tissue.
Thirty proteins showed similar trends of alterations in both
vaginal and cervical cancer compared with normal vaginal tissue,
which might indicate common carcinogenetic pathways and reflect
the underlying pathogenesis to the diseases. However, three proteins
were significantly altered in vaginal cancer exclusively (DEAD box,
erbB3-binding protein and biliverdin reductase), and six proteins in
cervical cancer (peroxiredoxin 2, annexin A2, sarcomeric tropo-
myosin kappa, Rnas inhib chain A and prolyl-4-hydrolase beta).
These proteins may constitute valuable markers for diagnosis,
prognosis or therapy, but this has to be confirmed in future studies.
Some of the proteins identified are discussed below and repre-
sent different categories involved in cellular pathways. Alterations
were detected among tumour suppressor proteins, oncoproteins,
proteins involved in the ubiquitin–proteasome pathway, in detoxi-
fication and antioxidation, stress-related proteins and cytoskeletal
proteins. Some of these proteins have previously been described in
other carcinomas, whereas others, to our knowledge, are not
associated with these tumours.
Tumour suppressor proteins and oncoproteins
The DEAD box protein The DEAD box protein family of RNA
helicases constitutes a large group of essential enzymes involved in
all aspects of RNA metabolism, including transcription, splicing and
translation (Abdelhaleem, 2004; Cordin et al, 2006). Based on their
distribution patterns, members of this family are thought to be
involved in different biological processes such as cellular growth
and division (www.ncbi.nlm.nih.gov). Furthermore, these proteins
may regulate p21
waf1/cip1 transcription independently of p53
suggesting it may be a tumour suppressor gene (Chao et al, 2006).
The DEAD box protein 48 identified in vaginal carcinoma in this
study has also been detected in pancreatic cancer and has been
suggested as a potential serum marker (Xia et al, 2005).
ErbB3-binding protein 1 ErbB3-binding protein 1 (Ebp1) is a
member of the family of proliferation-associated 2G4 proteins
(PA2G4s) and plays a role in cellular growth and differentiation. It
induces activation of the transmembrane receptor erbB3 (Kowalinski
et al, 2007), which activates the ras pathway. The Ras–raf–mek
pathway is the major downstream signalling pathway that emanates
from all EGFR complexes. The EGFR signalling system comprises
the four transmembrane proteins erbB1–erbB4, with intracellular
tyrosine domains and extracellular ligand-binding domains. In
vaginal cancer, the erbB3-binding protein was upregulated, indicating
involvement of the ras pathway. In another study, Ebp1 overexpres-
sion resulted in downregulation of the androgen receptor leading to
reduced incidence of androgen-dependent prostate tumours and
slower tumour growth (Zhang et al, 2005b). To our knowledge this
protein has not been described in any other carcinoma.
Ras 1B Ras 1B was overexpressed in both vaginal and cervical
cancer cells, which further points to involvement of ras oncogenes
in the carcinogenesis of these malignancies.
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Figure 2 Global differential expression of some of the identified proteins between normal vaginal tissue, vaginal and cervical carcinoma (red¼normal,
green¼vaginal cancer and orange¼cervical cancer).
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sThe family of ras oncogenes has been extensively studied
in human malignancies. Ras proteins play a direct causal role
in human cancer and in other diseases. Mutations in the different
ras oncogenes (H-Ras, N-Ras and K-Ras) occur in varying
frequencies in different tumour types. RAS-mediated signals
lead to effects on cell growth, differentiation, cycling and survival.
Other cellular consequences of Ras activation include inter-
actions with the Rho-family proteins. In gynaecological cancers,
mutations of the K-Ras have been detected in endometrial
(0–47%), cervical (0–61%) and ovarian carcinoma (0–46%;
Mammas et al, 2005).
Alterations of other proteins that are supposed to function
as tumour suppressors and oncoproteins were detected
(14-3-3 proteins, RhoGDI2 protein, TEF1d, DJ-1, Gelsolin and
hnRNP H1).
The 14-3-3 proteins The 14-3-3 proteins belong to an important,
abundant highly conserved family that interact with many cellular
proteins at their phosphorylation sites and the target proteins
regulate various processes such as stress response, cell-cycle
control, signal transduction and apoptosis (van Hemert et al, 2001;
Hermeking, 2006). Seven different isoforms of these small acidic
polypeptides of 28–33kDa have been detected. One isoform 14-3-3
s (¼sigma) has been directly implicated in the aetiology of human
cancer. It is induced by DNA damage and appears to be required
for maintaining the G2/M checkpoint in epithelial cells, and its
gene is directly regulated by p53 (Hermeking, 2003). Absent or
decreased expression of 14-3-3 s has been found in different
cancers, such as vulvar cancer (Gasco et al, 2002), breast cancer
(Urano et al, 2002), bladder cancer (Ostergaard et al, 1997) and
neuroendocrine lung tumours (Yatabe et al, 2002).
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• RNAs inhib chain A  
• Prolyl-4-hydrolase

• Deadbox protein  
(DDX48)
• ErbB3 binding  prot
• Biliverdin reductase
Downregulated:
•Calreticulin
•Tropomyosin 2 
•Vimentin
•Gelsolin
•Vinculin
•Filamin
Upregulated (some of them):
•Tyr-3-monooxygenase
•14-3-3 protein theta
•Nuclear chloride channel prot
•Proteasome activator A28 beta 
•RAB 1B
•GST M2-2 samt M1
•HSP 27
•Eukar. transl elongation factor 
•GDP dissociation inhibitor
•Capping prot (actin filament)
•DJ-1
•NM23
Common
proteins
Figure 3 Venn diagram showing the proteins that were uniquely and similarly expressed in vaginal and cervical carcinomas. The arrows indicate up- or
downregulation.
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sIn this study, three other isoforms were detected: 14-3-3 theta,
zeta and epsilon, which might be implicated in the genesis of
vaginal and cervical cancers. Previously, 14-3-3 epsilon and zeta
proteins have been shown to play a role in RAS/MAP kinase
pathways (Yip-Schneider et al, 2000). Similar to our findings,
downregulation of the 14-3-3 epsilon protein has been described in
cervical carcinoma (Bae et al, 2005), and overexpression of 14-3-3
zeta in lung cancer cells (Qi and Martinez, 2003) and oral
squamous cell carcinoma (Matta et al, 2007).
GDP dissociation inhibitors GDP Dissociation Inhibitors (RhoG-
DIs) are important regulators of the Rho proteins that sequester
the GDP – bound Rho proteins in cytoplasm.
Rho proteins are involved in motility and metastasis of cancer
cells through regulation of cell morphology and the actin cyto-
skeleton. RhoGDI2 has been identified as a metastasis suppressor
gene, a marker of aggressive human cancer (Gildea et al, 2002).
Genomic analyses of metastatic melanoma cells have shown
overexpression of RhoC protein, indicating an important role of
the protein in tumour invasion (Clark et al, 2000). Increased
expression of Rho proteins has been detected in bladder cancer
and seems to be involved in occurrence and progression of the
cancer and may be valuable prognostic markers (Kamai et al,
2003).
In contrast to our results, reduced expression of RhoGDI2 has
been demonstrated in bladder cancer (Theodorescu et al, 2004)
and cervical SCC (Bae et al, 2005) and was associated with
decreased survival in bladder cancer (Theodorescu et al, 2004) and
lymph node metastasis in breast cancer (Hu et al, 2007).
The high expression of RhoGDI2 found in this study could
possibly be explained by detection of these diseases at an early
stage of cancer progression before downregulation of the GDP
dissociation inhibitor 2 gene.
Eukaryotic translation elongation factor 1d Eukaryotic transla-
tion elongation factor 1d (TEF1d) is a newly discovered protein
(Joseph et al, 2002) that has been shown to be a protooncogene
causing tumourigenetic growth in nickel-treated human bronchial
epithelial cells (Lei et al, 2006). High expression of TEF1d was
detected in NSCLC (Liu et al, 2004), which is consistent with our
data.
DJ-1 is a 20kDa ubiquitous cytoplasmic and nuclear oncogene
product also known as PARK7. It is involved in multiple
physiological processes including cancer, Parkinson’s disease and
male fertility (www.ncbi.nlm.nih.gov). According to a recent study
overexpression of DJ-1 has protective effects on apoptosis
associated with its ability to decrease the Bax level by inhibiting
p53 transcriptional activity (Fan et al, 2008). High DJ-1 expression
has been demonstrated in carcinomas of lung, breast and prostate
(Hod, 2004; Fan et al, 2008), which is also consistent with our
findings. In lung cancer this was correlated with poor clinical
prognosis (Kim et al, 2005) and in breast cancer it has been
associated with decreased expression of tumour suppressor
phosphatase and deletion of the tensin homologue on chromo-
some 10 (PTEN; Kim et al, 2005).
Gelsolin Gelsolin is an 82kDa actin-binding protein. A gelsolin
gene mutation has been found in familial amyloidosis (Haltia et al,
1992; Kamada et al, 1998). Studies have noted that overexpression
of gelsolin prevent apoptosis (Ohtsu et al, 1997), whereas caspase-
cleaved gelsolin can cause apoptotic cell death (Kothakota et al,
1997). Thus, gelsolin seems to have a dual function, as also
proposed for Bcl-2 (Kamada et al, 1998). It has been noted that
cells with overexpressed gelsolin have a prolonged S phase
followed by a delay in G2, suggesting that downregulation of
gelsolin may lead to malignant transformation by attenuating G2
checkpoint function (Sakai et al, 1999). Similar to our results,
reduced expression of gelsolin has been detected in human gastric
(TMK1) and urinary bladder (UMUC2) cancer cell lines, and has
further been associated with mutated TP53 and shorter survival in
bladder carcinoma (Sanchez-Carbayo et al, 2007).
Antioxidation and detoxification
Several proteins involved in protein degradation, antioxidation
and detoxification have been identified. Biliverdin reductase was
upregulated in vaginal carcinoma, but not in cervical carcinoma.
Upregulation of thiol-specific antioxidant was detected in cervical
cancer, whereas prolyl-4-hydrolase beta was downregulated in
cervical cancer.
Other antioxidants and detoxification proteins such as GST,
Proteasome activator hP A28 beta, aldehyde dehydrogenase, serine
protease inhibitor and PIMT have shown elevated expression in
both vaginal and cervical cancer.
Biliverdin reductase Biliverdin reductase (BVR) is a serine/
threonine/tyrosine kinase that catalyses reduction of biliverdin to
bilirubin. BVR is a zinc metalloprotein, thought to protect the
cell from oxidative damage (Baranano et al, 2002; Lerner-
Marmarosh et al, 2005). In concordance with our results, increases
in biliverdin reductase expression have been detected in other
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Figure 5 Cluster analysis using the expression patterns of nine identified proteins that are uniquely expressed in both vaginal and cervical carcinoma.
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scarcinomas; renal cell (Maines et al, 1999) and hepatocellular
carcinoma (Melle et al, 2007).
Thiol-specific antioxidants Thiol-specific antioxidants (TSAs),
also referred to as thiol peroxidases (TPx), comprise a novel
family of thiol-specific antioxidant enzymes, that provides a
protective role in cells via peroxidase (Shin et al, 2005). There are
five peroxiredoxins (Prx) genes. TSA 1p was the first peroxi-
redoxin to be identified and has been shown to be the major
thioredoxin peroxidase in cytoplasm (Wong et al, 2002). The
members of the peroxiredoxin family have diverse functions
associated with various biological processes including detoxifica-
tion of oxidants, cell proliferation, cell differentiation and gene
expression (Fujii and Ikeda, 2002; Jang et al, 2004). Altered
expression of different peroxiredoxins has been identified in
several malignancies, such as in hepatocellular carcinoma (Melle
et al, 2007), cervical carcinoma (Bae et al, 2005), gastric carcinoma
(Jang et al, 2004), clear cell ovarian adenocarcinoma (Morita et al,
2006) and prostate carcinoma (Ahram et al, 2002). In accordance
with our findings, upregulation of TSAs (peroxiredoxin 2) has
been detected in HPV16 E7-expressing cervical carcinoma cells
(Lee et al, 2005). Studies have also shown that overexpression of
peroxiredoxin 2 protein inhibits cisplatin-induced apoptosis,
thereby contributing to chemoresistance in tumour cells (Chung
et al, 2001).
Prolyl-4-hydrolase beta Prolyl-4-hydrolase beta is a detoxifica-
tion enzyme. Prolyl-4-hydrolase beta-isoform (P4HB) was found to
be upregulated in HER-2/neu-positive breast tumours (Zhang et al,
2005a) in contrast to our findings.
The ubiquitin–proteasome pathway The ubiquitin–proteasome
pathway plays a major role in non-lysosomal degradation of
dysfunctional intracellular proteins in eukaryotes. Proteins that are
degraded by the ubiquitin–proteasome mechanism are first
conjugated to ubiquitin. Ubiquitinated proteins are recognised
by the 26S proteasome (Hasselgren and Fischer, 1997). Protea-
somes can be activated by two different types of regulatory
complexes. One is the proteasome activator hP A28 beta (Rivett
et al, 1997). Alterations in ubiquitination and deubiquitination
reactions have been directly implicated in the aetiology of many
malignancies. Some of the natural substrates for degradation by
the proteasome are oncoproteins that, if not properly removed
from the cell, may induce malignant transformation (Ciechanover
and Schwartz, 2004).
It has been noted that the tumour suppressor protein p53 level is
extremely low in uterine cervical carcinoma tumours caused by
high-risk HPV, (for example, HPVs 16 and 18). Studies have shown
that the suppressor is targeted for ubiquitin-mediated degradation
by the HPV oncoprotein E6 coded by high-risk strains of the virus
(Scheffner and Whitaker, 2003). The viral oncoproteins exploit the
ubiquitin–proteasome system to degrade and thus functionally
inactivate negative cell-regulatory proteins including pRb and p53.
Upregulation of the 26S proteasome subunit has been detected
in HPV16 E7expressing cervical carcinoma cells (Lee et al, 2005).
In accordance with our results, upregulation of proteasome acti-
vator hP A28 beta have been detected in breast cancer (Somiari
et al, 2003) and of proteasome activator complex subunit 2 in
gastric cancer (Jang et al, 2004). Our results could support
involvement of the ubiquitin–proteasome pathway in vaginal and
cervical carcinogenesis.
Heat shock proteins Heat shock proteins (HSPs) are required for
cell survival under stressful conditions and are overexpressed in a
number of human cancers. HSPs have antiapoptotic properties
that protects the cell from programmed cell death and they are
involved in cancer immunity (Calderwood et al, 2006; Multhoff,
2006). HSP 27 is principally found in cells from tissues such as
breast, uterus, cervix, placenta and skin as well as in platelets
(Ciocca et al, 1993). High expression in cancer cells has been
shown to correlate with prognosis and drug resistance. Increased
expression of HSP 27 has been identified in ovarian (Langdon et al,
1995; Geisler et al, 1999), cervical (Bae et al, 2005) and endometrial
carcinoma and correlates with good prognosis. Similarly, in this
study, HSP 27 was upregulated in the cancer specimens and this
may also correlate with a good prognosis, because these cases were
discovered at early stage. Conversely, HSP 27 overexpression has
been recognised as a negative prognostic indicator in breast
(Lemieux et al, 1997) and gastric (Ciocca et al, 1993; Kapranos
et al, 2002) carcinoma.
Calreticulin Calreticulin (CR) is a multifunctional calcium-
binding protein present in the endoplasmic reticulum (ER) of
the cell nucleus. It is an important molecular chaperone involved
in ‘quality control’ within secretory pathways and has important
regulatory functions such as modulation of steroid hormone
receptors, retinoic acid receptors and regulation of cell adhesion.
Increased levels of calreticulin have been reported in hepatocel-
lular, colon, prostate and bladder carcinomas and as well as in
radioresistant squamous carcinoma (Ramsamooj et al, 1995;
Alaiya et al, 2000; Yoon et al, 2000; Brunagel et al, 2003; Iwaki
et al, 2004).
In accordance with our results, downregulation of calreticulin
has been noted in other squamous cell carcinomas, such as
primary laryngeal and maxillar squamous cell carcinoma (Ogino
et al, 2003, 2006).
Impaired p53 expression, function and nuclear localisation have
been observed in calreticulin-deficient cells and the level of
calreticulin (CRT) has been correlated with the rate of apoptosis
(Mesaeli and Phillipson, 2004). Calreticulin plays a role in the
control of cell adhesion via regulation of vinculin expression,
which is downregulated in cells expressing reduced levels of
calreticulin. Downregulation of calreticulin increases cell motility
and decreases cell spreading (Opas et al, 1996).
Cytoskeletal proteins
Alterations of several cytoskeletal proteins were identified in this
study. Upregulation of annexin A2 was found in cervical cancer. In
both vaginal and cervical carcinoma there was a downregulation of
vimentin, filamin, tropomyosin 2 (TM2 beta) as well as vinculin.
The intermediate protein family includes several hundred
members (such as cytokeratin, vimentin, actin, filamin, tropo-
myosin) and form the cytoskeletal network together with two other
filament system (microfilament and microtubules). In high-grade
dysplastic cervical cells filamin, vimentin and vinculin were
upregulated (Gu et al, 2007) in contrast to the findings in cancer
cells in our study.
Annexins Annexins are calcium-dependent phospholipid-bind-
ing proteins and play a role in regulating the cytoskeleton and cell
motility (Benz and Hofmann, 1997). Several annexins have been
implicated in the pathogenesis of benign and malignant neoplasms
of different origins. In some tumours a suppressive action of
annexins has been shown, whereas in other tumours annexins have
been involved in progression (Bastian, 1997; Hayes and Moss,
2004). Annexin A2 has been implicated in progression, migration
and metastatic potential (Gillette et al, 2004; Hayes and Moss,
2004). Upregulation of annexin A2 (in line with our results) and A5
has been described in cervical carcinoma; however, annexin A1
was downregulated suggesting different roles for these annexins in
the carcinogenesis of cervical squamous cell carcinoma (Bae et al,
2005). Upregulation of annexin A2 has been reported in many
malignancies, such as buccal SCC (Chen et al, 2004), pancreatic,
gastric, breast and brain cancer (Hayes and Moss, 2004; Tatenhorst
et al, 2006). In renal carcinoma annexin 2 has been suggested as a
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suseful prognostic marker (Zimmermann et al, 2004). However,
reduced or lost expression of annexin 2 has been noticed in
prostate carcinoma (Liu et al, 2003a) and osteosarcoma (Gillette
et al, 2004) and has been related to aggressive behaviour and
metastatic potential.
Tropomyosins Tropomyosins (TMs) are actin-binding proteins.
TMs isoforms and actin, are the two major structural constituents
of microfilaments. The high-molecular-weight tropomyosins
are thought to play a role in stabilising the organisation of
actin filaments, which in turn plays an important role in the
maintenance of cell shape, cell motility, and cell–cell and cell–
matrix interactions (Button et al, 1995). Many TM isoforms,
including tropomyosin-1 (TM1), are downregulated in trans-
formed cells. The loss of tropomyosin expression in tumour cells
may prevent proper assembly of microfilaments and, thereby
contribute to the invasive and metastatic properties of cancer
cells (Shah et al, 2001). In bladder carcinoma alterations in TM
expression (reduced TM1, 2 and 3) seem to be an early event in
bladder carcinogenesis (Pawlak et al, 2004). Similar to our
findings, low expression of TM1 and TM2 has been detected in
cervical carcinoma (Bae et al, 2005), of TM2 in oesophageal
squamous cell carcinoma (Jazii et al, 2006) and of TM1 in breast
carcinoma (Franzen et al, 1996; Raval et al, 2003). However, higher
levels were found in primary breast cancer that had metastasised to
the axillary lymph nodes (Franzen et al, 1996).
Alpha-2-actin Alpha-2-actin, the human aortic smooth muscle
actin gene, is one of six different actin isoforms, which have been
identified. Actins are highly conserved proteins that are involved
in cell motility, structure and integrity. Alpha actins are a major
constituent of the contractile apparatus (www.ncbi.nlm.nih.gov).
In this study, high expression of alpha-2-actin was noted in
cervical carcinoma.
Vimentin Vimentin is a type III intermediate filament protein
that is frequently expressed in epithelial carcinomas and correlates
with invasiveness and poor prognosis. Ablation of vimentin
expression inhibits migration and invasion of colon and breast
cancer cell lines (McInroy and Maatta, 2007) and promotes conver-
sion of tumourigenic prostate epithelial cells into slow growing,
less aggressive cells (Liu et al, 2003b). Upregulation of vimentin
has been reported in prostate cancer, lung cancer and carcino-
sarcoma and vimentin have been used as a marker for lung cancer
detection (Liu et al, 2004; Wu et al, 2007; Pardo et al, 2008; Wei
et al, 2008). In colorectal tumours, increased vimentin expression
correlates with the presence of oncogenic KRAS and with nuclear
beta-catenin. However, corresponding liver, lymph node, brain
and lung metastases did not express vimentin (Veenendaal et al,
2008), indicating other pathways in secondary colorectal tumours.
Similar to the proteomic study of cervical carcinomas (Bae et al,
2005), but in contrast to the findings in other carcinomas, we
found a downregulation of vimentin in both vaginal and cervical
carcinoma, suggesting alternative pathways for epithelial–
mesenchymal transition.
Vinculin and filamin Vinculin and filamin are actin-binding
proteins (ABPs) that provide structure and allow cells to be
mobile. Studies have shown that filamin A integrates with beta-1
integrins to mediate cell spreading and prevent apoptosis (Kim
et al, 2008). Furthermore 14-3-3 proteins bind both filamin and
beta-2 integrin and induce distal signalling pathways leading to
dramatic changes in the cytoskeleton, transcription and activation
of integrins, which mediate adhesion (Nurmi et al, 2006).
A previous study showed that filamin-A interacts with BRCA2,
and lack of filamin-A expression results in increased cellular
sensitivity to several DNA-damaging agents in melanoma cells
(Yuan and Shen, 2001).
Vinculin is thought to function as one of several interacting
proteins involved in anchoring F-actin to the membrane (www.
ncbi.nlm.nih.gov).
Low levels of vinculin have been found in highly malignant
neuroendocrine tumours. Therefore vinculin is thought to play a
role in growth regulation of neuroendocrine tumours (Liu et al,
2007). Similarly, in this study, low levels of both vinculin and
filamin were detected in vaginal and cervical carcinoma, indicating
that these proteins are important for malignant transformation.
There is not much data in the literature regarding vinculin and
filamin expression in malignancies.
Other proteins
Rnas inhib chain A Rnas inhib chain A or human ribonuclease
inhibitor (hRI) is an acid protein with a molecular weight
of 50kDa, which can inhibit the activity of pancreatic RNase
(RNase A). Furthermore, RI is a highly efficient inhibitor of
angiogenin, which is a member of the ribonuclease super family.
Because angiogenin is an important angiogenic factor, it has been
hypothesised that RI may be a latent antiangiogenic drug (Fu et al,
2005).
hRI was downregulated exclusively in cervical cancer. This
finding may indicate that this protein is important for angio-
genesis in cervical carcinoma and could possibly be an effective
angiogenetic inhibitor in this specific type of cancer. To our
knowledge this is the first time that this protein has been observed
in cancer tissue.
The chloride intracellular channel The chloride intracellular
channel (CLIC) gene family has been implicated in chloride ion
transport within various subcellular compartments (Berryman and
Bretscher, 2000).
Antisense suppression of the chloride intracellular channel
family induces apoptosis, and inhibits tumour growth (Suh et al,
2005). The cell- and tissue-specific patterns of CLIC1 expression
suggest it may play distinct roles in different cell types (Ulmasov
et al, 2007).
In accordance with our study elevated CLIC1 levels have been
reported in hepatocellular carcinoma (Huang et al, 2004) and
gastric carcinoma (Chen et al, 2007) and in gastric cancer this was
strongly correlated with lymph node metastasis, lymphatic
invasion, perineural invasion and pathological staging indicating
that CLIC1 could be a potential prognostic marker (Chen et al,
2007). Otherwise, the literature contains little data on this protein
and its relationship to cancer.
This study has shown alterations and interactions of several
proteins, such as proteins involved in inactivation of p53 (DEAD
box, the ubiquitin–proteasome pathway, 14-3-3 protein), activa-
tion of the RAS pathway (erbB3-binding protein) and proteins
implicated in apoptosis (Dj-1, Gelsolin, hnRNPH1). Alterations
of cytoskeletal proteins were another important finding not
previously described for these carcinomas.
In accordance with our findings in cervical carcinoma Bae et al,
2005 detected upregulation of annexin A2 and downregulation of
vimentin and tropomyosins 1 and 2, which might indicate that
these cytoskeletal proteins are involved in tumourigenesis and
could be useful markers. Interestingly, two previously relatively
unknown proteins, the angiogenic factor human ribonuclease
inhibitor and the detoxification enzyme prolyl-4-hydrolase beta,
were distinctly downregulated in cervical carcinoma.
In summary, the protein variations identified in this study,
indicate that numerous cellular pathways are activated leading to
interaction of multiple proteins during vaginal and cervical
tumourigenesis, which underscore the complexity of the cellular
signalling networks responsible for the development and progres-
sion of cancer.
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sSome proteins were similarly altered in both vaginal and cervical
carcinomas, suggesting common carcinogenetic pathways. How-
ever, certain proteins showed different levels of expression among
the three tissue specimens, indicating that these could be specific
tumour markers.
These data verify that proteomic analysis can provide
extensive information to better understand the pathogenesis and
oncogenesis of malignancies and further provide a basis to develop
useful molecular markers for diagnosis, prognosis and therapy.
The fact that multiple cellular pathways seem to be involved
indicates that multiple proteins should be simultaneously targeted.
However, further studies are needed to confirm the results from
this study.
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